Table 2.
Total (n = 16) | AHI < 30 events/h | AHI ≥ 30 events/h | P | |
---|---|---|---|---|
(n = 5) | (n = 11) | |||
Age, y | 62.4 ± 11.5 | 64.2 ± 10.9 | 63.3 ± 11.4 | > .99 |
Sex, male | 15 | 4 | 11 | .31 |
BMI | 26.8 ± 4.2 | 25.8 ± 4.3 | 27.2 ± 4.3 | .46 |
Smoker, PKY | 43.1 ± 40.5 | 20.0 ± 15.8 | 53.6 ± 44.3 | .09 |
ECOG status | 1 ±.6 | .8 ± .4 | 1.1 ± .7 | .43 |
Polysomnography | ||||
AHI | 43.3 ± 29.4 | 10.8 ± 8.9 | 59.5 ± 20.8 | < .01* |
ODI | 28.2 ± 25.8 | 7.8 ± 4.0 | 41.0 ± 25.5 | < .01* |
Lowest SpO2 | 81.8 ± 6.9 | 84.0 ± 5.3 | 80.7 ± 7.5 | .50 |
Tsat90% | 19.1 ± 27.1 | 2.5 ± 2.1 | 29.5 ± 31.5 | .05 |
Tsat90 mins | 29.8 ± 56.6 | 5.2 ± 5.0 | 41.0 ± 66.0 | .16 |
PFS, months | 18.4 ± 29.2 | 42.4 ± 45.2 | 7.5 ± 6.3 | .03* |
3-y mortalitya (%) | 81.3 | 40 | 100 | .08 |
5-y mortalitya (%) | 93.7 | 80 | 100 | .31 |
Cancer stage (%) | .55 | |||
Stage III | 4 (25) | 2 (40) | 2 (18) | |
Stage IV | 12 (75) | 3 (60) | 9 (82) | |
Pathology (%) | .59 | |||
Adenocarcinoma | 10 (66) | 4 (80) | 6 (55) | |
Squamous cell | 3 (18) | 1 (20) | 2 (18) | |
Other | 3 (18) | 0 (0) | 3 (27) | |
EGFR mutation | 7 | 3 | 4 | > .99 |
No mutation | 3 | 1 | 2 | |
First-line cancer treatment | .36 | |||
Target therapy | 4 | 3 | 4 | |
CCRT | 3 | 2 | 1 | |
Chemotherapy | 4 | 0 | 4 | |
Radiotherapy | 1 | 0 | 1 | |
Supportive care | 1 | 0 | 1 | |
Comorbid disease | ||||
COPD | 1 | 0 | 1 | > .99 |
Ischemic heart disease | 4 | 1 | 3 | > .99 |
Diabetes mellitus | 5 | 1 | 4 | > .99 |
Hypertension | 8 | 2 | 6 | > .99 |
Data presented as mean ± SD or number (percentage). *Cancer-related mortality. BMI = body mass index, CCRT = concurrent chemoradiotherapy, COPD = chronic obstructive pulmonary disease, ECOG = Eastern Cooperative Oncology Group, EGFR = epidermal growth factor receptor, ODI = oxygen desaturation index, PFS = progression-free survival, PKY = packs per year, SpO2 = oxygen saturation, Tsat90% = percentage of sleep time with oxygen saturation < 90%, Tsat90 mins = total sleep time (minutes) with oxygen saturation < 90%.